Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T08:30:01.207Z Has data issue: false hasContentIssue false
  • English
  • Français

Future Drugs for the Treatment of Depression: The Need to Look Beyond Monoamine Systems

Published online by Cambridge University Press:  07 November 2014

Mark Hyman Rapaport
Get access Rights & Permissions [Opens in a new window]

Extract

Review of extant biological data would suggest that major depressive disorder (MDD) is a term used to subsume a syndrome that may involve a variety of different pathophysiological processes. Current research has implicated a myriad of different factors in the pathogenesis of depressive disorders including: genetic predisposition, “hormonal” abnormalities, disturbances in neurostransmitters, disturbances in neurocircuitry, and immune dysfunction. Our most recent consensus suggests that the depressive disorders reflect the interplay between these biological systems and psychosocial experiences, such as early-life trauma and current life stressors. Thus, MDD truly represents a complex heterogeneous syndrome. This conceptualization suggests that a variety of different types of treatment approaches will be necessary to adequately ameliorate the symptoms of patients suffering from this syndrome. Although this is a daunting task, we are beginning to develop approaches that will enable us to add to our armamentation of biological treatments.

Type
Expert Panel Supplement
Information
CNS Spectrums , Volume 14 , Issue S5: Efficacy, Safety, and Tolerability Considerations in the Novel Treatment of Major Depressive Disorder , March 2009 , pp. 14 - 16
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Eaton, WW, Shao, H, Nestadt, G, Lee, HB, Bienvenu, OJ, Zandi, P. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry. 2008;65(5):513–520.CrossRefGoogle ScholarPubMed
2.Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.CrossRefGoogle ScholarPubMed
3.Owens, MJ, Nemeroff, CB. Corticotropin-releasing factor antagonists: therapeutic potential in the treatment of affective disorders. CNS Drugs. 1999;12:85–92.CrossRefGoogle Scholar
4.Owens, MJ, Nemeroff, CB. Corticotropin-releasing factor antagonists in affective disorders. Expert Opin Investig Drugs. 1999;8(11):1849–1858.CrossRefGoogle ScholarPubMed
5.Zarate, CA Jr, Du, J, Quiroz, J, et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system. Ann N Y Acad Sci. 2003;1003:273–291.CrossRefGoogle ScholarPubMed
6.Maeng, S, Zarate, CA Jr, Du, J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349–352.CrossRefGoogle ScholarPubMed
7.Kos, T, Legutko, B, Danysz, W, Samoriski, G, Popik, P. Enhancement of antidepressant-like effects but not brain-derived neurotrophic factor mRNA expression by the novel N-methyl-D-aspartate receptor antagonist neramexane in mice. J Pharmacol Exp Ther. 2006;318(3):1128–1136.CrossRefGoogle Scholar
8.Zarate, CA Jr, Singh, JB, Carlson, PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864.CrossRefGoogle ScholarPubMed
9.Malberg, JE, Eisch, AJ, Nestler, EJ, Duman, RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 2000;20(24):9104–9110.CrossRefGoogle ScholarPubMed
10.Pechnick, RN, Zonis, S, Wawrowsky, K, Pourmorady, J, Chesnokova, V. p21Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hippocampus. Proc Natl Acad Sci U S A. 2008;105(4):1358–1363.CrossRefGoogle ScholarPubMed
11.Müller, N, Schwarz, MJ, Dehning, S, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7):680–684.CrossRefGoogle ScholarPubMed
12.Miller, AH, Raison, CL. Cytokines, p38 MAP kinase and the pathophysiology of depression. Neuropsychopharmacology. 2006;31(10):2089–2090.CrossRefGoogle ScholarPubMed
13.Lin, PY, Su, KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry. 2007;68(7):1056–1061.CrossRefGoogle ScholarPubMed
14.McMahon, FJ, Buervenich, S, Charney, D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet. 2006;78(5):804–814.CrossRefGoogle ScholarPubMed
15.Paddock, S, Laje, G, Charney, D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181–1188.CrossRefGoogle ScholarPubMed
16.Hu, XZ, Rush, AJ, Charney, D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry. 2007;64(7):783–792.CrossRefGoogle ScholarPubMed
17.Laje, G, Paddock, S, Manji, H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530–1538.CrossRefGoogle ScholarPubMed